Tuesday, May 4, 2010

GLENMARK RACING AHEAD WITH APPROVALS /LICENCING ACTIVITIES


Glenmark Pharmaceuticals Limited

RACING AHEAD OF MANY COMPETITORS

As of this moment, Glenmark is yet to declare its 4th quarter  and annual results for FY10. However, in recent past, Glenmark has been securing several approvals for marketing /licensing several generics / drugs etc in various countries. These are being noticed by market with interest.

These point to a bright future for Glenmark in the days to come.

In the last 3 quarters, its Basic EPS on a face value of Rs.1 has been  5.25 for HY/E Sep 09 and  3.42 for q/e Dec 09 on consolidated basis.

Glenmark may very well improve on this in each succeeding quarter hereafter - judging from the progress it is making in securing various approvals in various countries and in marketing and Licesning activities.



SOME RELEVANT ANNOUNCEMENT MADE BY GLENMARK TO EXCHANGE




4-05-2010  : Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 04, 2010, titled "Glenmark Generics enters into an exclusive licensing agreement with Par Pharmaceuticals, USA to market Ezetimibe". 

03-05-2010          Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 03, 2010, titled "Sanofi-Aventis and Glenmark Pharmaceuticals Sign License Agreement - Development of Novel Agents to treat Chronic Pain".
    
29-04-2010          Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 29, 2010, titled "Glenmark launches Prasugrel for the first time in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

26-04-2010          Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 26, 2010, titled "Glenmark Generics receives USFDA approval for Norethindrone tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

12-04-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 12, 2010, titled "Glenmark Generics announces the settlement of Paragraph IV litigation with GSK". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

07-04-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 07, 2010, titled "Glenmark Generics receives UK-MA approval for Ropinirole film-coated tablets and to distribute Lercanidipine Hydrochloride film-coated tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

01-04-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 01, 2010, titled "Glenmark Generics receives approval from USFDA for Moexipril Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

31-03-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 31, 2010, titled "Glenmark Generics announced New Drug Applications for Oxycodone Hydrochloride Capsules and Liquid Solution". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). 

26-03-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 26, 2010, titled "Glenmark Generics receives approval from the USFDA for Calcipotriene Ointment". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements) 


18-03-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 18, 2010, titled " Glenmark Generics receives approval from the USFDA for Moexipril Hydrochloride Tablets". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).



02-03-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release vide its letter dated March 02, 2010, titled " Glenmark Generics receives approval from the USFDA for Ropinirole Hydrochloride Tablets". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). 




29-01-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 27691.66 lacs for quarter ending on 31-DEC-2009 against Rs. 24430.62 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 3748.51 lacs for the quarter ending on 31-DEC-2009 against Rs. 3691.96 lacs for the quarter ending on 31-DEC-2008.


29-01-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 64168.46 lacs for quarter ending on 31-DEC-2009 against Rs. 58138.94 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 9407.36 lacs for the quarter ending on 31-DEC-2009 against Rs. 8143.19 lacs for the quarter ending on 31-DEC-2008.


29-01-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 29, 2010, titled "Glenmark's consolidated revenue increases by 10% to Rs. 6416.85 Mn for Q3-FY'10. Consolidated Net Profit increases by 15.5% at Rs.940.73 million". The Company has further submitted to the Exchange a copy of the Management Discussion and Analysis for the Third quarter of the Financial Year 2009-10 ended December 31, 2009. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).


22-01-2010          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 22, 2010, titled "Glenmark Generics Ltd granted tentative approval by US-FDA for Trandolapril and Verapamil Hydrochloride extended-release tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

24-12-2009          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 24, 2009, titled "Glenmark Generics Ltd receives Tentative Approval from USFDA for Pramipexole Dihydrochloride tablets and Atomoxetine Hydrochloride capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).


16-12-2009          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 16, 2009, titled "Glenmark in-licenses its first product from Stratpharma AG, Switzerland for scar management therapy in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

16-11-2009          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 16, 2009, titled "Glenmark Pharmaceuticals outlicenses a specialty pharmaceutical product to medicis pharmaceutical for the North America Region". A copy of the press release shall be available on the NSE website
16-11-2009          Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 14, 2009, titled "Glenmark Generics receives ANDA approval from US-FDA for Ciclopirox Olamine Cream". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). 




SOME RECENT NEWS ABOUT GLENMARK

DT 04.05.2010


Glenmark Pharmaceuticals S.A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announced today that it has entered into an agreement with Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) to grant Sanofi-Aventis a license for the development and commercialization of novel agents to treat chronic pain.

Under the terms of the agreement, Glenmark will receive an upfront payment of US $ 20 million, as well as development, regulatory and commercial milestone payments. All such payments could reach a total of U.S. $ 325 million. 

 In addition, Glenmark is eligible to receive tiered double-digit royalties on sales of products commercialized under the license.


Sanofi-aventis will have exclusive marketing rights for North America, European Union and Japan subject to Glenmark's right to co-promote the products in the United States and five Eastern European countries. Sanofi- aventis will also have co-marketing rights in 10 other countries including Brazil, Russia, and China, whereas Glenmark will retain exclusive rights in India and other countries of the rest of the world.


“There continues to be a medical need for safer and more efficacious products for the treatment of painful diabetic neurophathy and osteoarthritis pain,” said Marc Cluzel, M.D., Executive Vice President, Research & Development, sanofi-aventis. “GRC 15300 and its associated program brings an innovative approach to sanofi-aventis’ pain portfolio. We are very pleased to collaborate with Glenmark Pharmaceuticals on the development of this new programme, which we believe may have promise to address a significant gap in treating chronic pain.”


According to Glenn Saldanha MD and CEO of GPL, “This agreement continues to 
demonstrate Glenmark’s world class innovative R&D and validates Glenmark’s leadership in the Indian drug discovery arena. We have made excellent progress with our TRPV3 program at Glenmark and are very excited to be joining our efforts with those of sanofiaventis, a world class research driven global pharmaceutical company.”




NEWS DT 29TH APRIL 2010

Glenmark launches Prasugrel for the first time in India
• A revolutionary new antiplatelet drug for the management of Acute
Coronary Syndrome with PCI
• Estimated market size at Rs. 300 crores


NEWS DT 26-04-2010


Glenmark Generics receives USFDA approval for Norethindrone tablets
• This is the first approval for an Indian company in the USD 4.5 billion dollar oral contraceptive segment
• The product will be marketed under the brand name Heather®:

NOTE : Many Indian pharma companies are securing such approvals and quickly marketing / licensing the marketing of their generics / drugs in many financially lucrative markets. Glenmark  appears to have stepped up SPEED. Looks like, it is likely to race ahead of many companies.

1 comment:

  1. It was a awe-inspiring post and it has a significant meaning and thanks for sharing the information. Would love to read your next post too...

    Thanks

    Regards:

    Share Market

    ReplyDelete